Haplo‐identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study

• Published in: British journal of haematology 2016-10, Vol.175 (2), p.265-274
• Main Authors: Xu, Lan‐Ping, Wang, Shun‐Qing, Wu, De‐Pei, Wang, Jian‐Min, Gao, Su‐Jun, Jiang, Ming, Wang, Cun‐Bang, Zhang, Xi, Liu, Qi‐Fa, Xia, Ling‐Hui, Wang, Xin, Huang, Xiao‐Jun
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Anemia, Aplastic - diagnosis; Anemia, Aplastic - etiology; Anemia, Aplastic - mortality; Anemia, Aplastic - therapy; Biomarkers; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease - epidemiology; Graft vs Host Disease - etiology; haematopoietic stem cell transplantation; haploidentical; Haplotypes; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - methods; HLA Antigens - genetics; Humans; Incidence; Male; Middle Aged; Prospective Studies; Retreatment; severe aplastic anaemia; Severity of Illness Index; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.14225

Summary We conducted a prospective, multicentre study to confirm the feasibility of haplo‐identical transplantation in treatment of severe aplastic anaemia (SAA) as salvage therapy, by analysing the outcomes of 101 patients who received haplo‐identical transplantation between June 2012 and October 2015. All cases surviving for more than 28 d achieved donor myeloid engraftment. The median time for myeloid engraftment was 12 (range, 9–25) days and 15 (range, 7–101) days for platelets, with a cumulative platelet engraftment incidence of 94·1 ± 0·1%. With a median follow‐up of 18·3 (3·0–43·6) months, recipients from haplo‐identical transplantation had more cumulative incidence of grade II–IV acute graft‐versus‐host disease (aGVHD, 33·7% vs. 4·2%, P